Founded in 1991, ImaRx Pharmaceutical Corp. designs, develops and markets pharmaceuticals for medical imaging (MRI, ultrasound and computed tomography) for the radiological imaging industry.
ImaRx Pharmaceutical Corp., announced 1999 that it has been acquired by E.I DuPont de Nemours & Co., Inc. The terms of the acquisition provide a royalty-free licensing arrangement with a newly-formed company, ImaRx LLC ("LLC"), to pursue and develop new products and technologies for drug and gene delivery independent from DuPont.
Yamanouchi Pharmaceutical Co. Ltd., ImaRx' licensee for Asian territories for this product, will continue to develop the product in Asia as DuPont's licensee. ImaRx LLC will have ownership of all other targeted and therapeutic products previously owned by ImaRx, including imaging products outside of diagnostic ultrasound imaging and two other imaging products, SonoRx® and LumenHance® LumenHance®, which are both FDA approved and licensed to BRACCO Diagnostics.
|Ultrasound Related Product Lines:|
| Contrast Agents:|
1635 East 18th Street
Tucson AZ 85719-6803